Nihon Medi-physics Co., Ltd.

This early-phase study tested a new imaging drug called NMK89 in 10 people with pancreatic cancer. The drug is designed to attach to a protein (MUC5AC) found on some pancreatic cancer cells and show up on PET scans. The main goal was to check safety and how well the imaging works…